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sibility of data collection through the Internet as a post marketing surveillance tool. In-
hospital MACE rates are low, and comparable to those observed in the clinical trials.
Comprehensive 12-month clinical follow-up will be available at the time of presentation.
9:00 a.m.
862-3 Subacute Stent Thrombosis After Successful Placement 
of Sirolimus-Eluting Coronary Stents: Real-World 
Experience
Allen Jeremias, Jonathan Bridges, Brian Bigelow, Brett Sylvia, Kalon K. Ho, Duane S. 
Pinto, David J. Cohen, Donald E. Cutlip, Joseph P. Carrozza, Jr., Beth Israel Deaconess 
Medical Center, Harvard Medical School, Boston, MA
Background: Subacute stent thrombosis (SAT) is a rare but devastating complication of
intracoronary stent implantation. The incidence with potent anti-platelet therapy has been
reported to be between 0.5-1.9%. Recently, the sirolimus-eluting Cypher™ stent was
introduced in the US. The randomized SIRUS trial reported a 0.4% rate of SAT. However,
the Food and Drug Administration has received 47 reports of SAT that occurred in clinical
practice and the manufacturer has subsequently issued a warning letter. The aim of this
study was to evaluate the incidence and potential risk factors of SAT in patients receiving
the sirolimus-eluting stent outside of clinical trials.
Methods: Since the commercial introduction of Cypher™ stents to the US in April 2003,
all patients that received sirolimus-eluting stents at our institution were followed in a reg-
istry. Percutaneous coronary intervention was performed using standard techniques. All
patients were treated with aspirin pre- and clopidogrel or ticlopidine immediately post-
procedure. The primary endpoint of the study was the incidence of SAT at 30 days.
Results: A total of 456 patients underwent implantation of 608 sirolimus-eluting stents.
The mean stent diameter was 2.8±0.3 mm and the mean stent length was 19.7±5.7 mm.
There were no cases of SAT during the index hospitalization, with 4 cases reported after
discharge during the first 30 days post-stenting (mean onset 9±4 days). There was no
apparent difference in stent diameter (2.6±0.2 mm) or stent length (19.7±6.1 mm)
between patients with SAT and the rest of the population. Three of the 4 patients discon-
tinued anti-platelet therapy after hospital discharge and in one patient the sirolimus-elut-
ing stent was implanted in the setting of an acute myocardial infarction.
Conclusion: Even in ‘real world’ patients, the incidence of SAT after sirolimus-eluting
stent implantion is less than 1%, and within the expected range for bare metal stents. The
discontinuation of anti-platelet therapy appears to be the most important risk factor for the
development of SAT.
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Andrew T. L Ong, Pedro A. Lemos, Angela Hoye, Chourmouzios A. Arampatzis, 
Francesco Saia, Jiro Aoki, Carlos van Mieghem, Sjoerd H. Hofma, Pieter C. Smits, 
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Background:The true incidence of early stent thrombosis after sirolimus or paclitaxel-elut-
ing stent (PES) implantation in an unselected group is at present controversial. So far,
there has been no systematic collection of data to examine its true incidence in the real-
world setting.
Aim: To compare the real-world, tertiary referral institution incidence of angiographic
stent thrombosis in both sirolimus-eluting stents (SES) and PES with historical controls.
Method: Since April 2002, drug eluting stents (DES) have been the default strategy in
patients undergoing percutaneous coronary intervention at our institution. 1000 consecu-
tive patients treated with SES and 500 consecutive patients treated with PES were
defined as our sample population. The last 500 consecutive patients exclusively treated
with bare stents form our control group. Clopidogrel use was as follows: at least one
month following bare stent implantation, at least 3 months following SES implantation,
and at least 6 months following PES implantation. Early stent thrombosis is defined as
stent thrombosis occurring < 30 days after stent implantation.
Results: In our cohort, the incidences of early stent thrombosis are as follows: 
Conclusion: This is the first study to demonstrate that both SES and PES are safe and
are comparable to historical bare stent controls in the real world population of unselected
patients. There appears to be no statistical difference in the incidence of early stent
thrombosis in both DES groups.
9:30 a.m.
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J. Eduardo Sousa, Alexandre Abizaid, Marco A. Costa, Amanda Sousa, Fausto Feres, 
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Popma, Patrick W. Serruys, Institute Dante Pazzanese of Cardiology, Sao Paulo, Brazil
Background: Short-term (4-months) and intermediate-term (2-year) results after implan-
tation of sirolimus-eluting (Cypher™) stent in human coronary arteries have been
reported. Between 4 to 24 months intimal hyperplasia was consistently suppressed as
assessed by follow-up MLD that showed minimal changes, and IVUS percent obstruction
volume that increased minimally from 0.3±0.8% to 3.3±8.4%. The aim of this study is to
determine if deleterious pathobiologic responses are present after a long (4-year) follow-
up.
Methods: Thirty patients treated with Cypher™ stents for single de novo coronary
lesions (15 fast-release and 15 slow-release formulation) will complete 4-year follow-up
in February, 2004. Clinical follow-up and stress test will be performed in all patients.
Results: At present (45±2 months) there has been 3 cardiac events: one pt presented
with acute MI at 14 months due to non-target site coronary occlusion proximal to the
Cypher™ stent. Serial IVUS interrogation of this MI culprit lesion demonstrated plaque
progression with echo-lucent zones suggesting plaque instability. Another pt with a
patent Cypher™ at mid circumflex developed left main disease and was referred to
bypass surgery (non-TLR) and the third patient presented with lesion progression at the
proximal edge of a Cypher™ stent implanted at a proximal RCA two years after the index
procedure. This pt was treated with another Cypher™ (TLR). Therefore, for the entire
patient cohort, the event free survival of major cardiac events is 90%.
Conclusion: Thusfar, in the FIM experience, the sirolimus-eluting Cypher™ stent has
demonstrated safety and efficacy up to 45-month follow-up, with low rates of major car-
diac events. The complete 4-year follow-up results (available for presentation) should
definitively establish long-term safety and efficacy of SES.
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862-6 Stents Without Restenosis: Enough to Replace Bypass 
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Huw Griffiths, Ameet Bakhai, Douglas West, Anthony De Souza, Jonathan Clague, 
Simon Davies, Carl Brookes, Andrew Bishop, John Pepper, Carlo Di Mario, Royal 
Brompton Hospital, London, United Kingdom
Background: Drug eluting stents (DES) have been shown to have very low restenosis
across a range of lesion subtypes. We tested the hypothesis that their implementation
would permit a cost effective percutaneous approach to a majority of patients with multi-
vessel disease.
Methods: Two experienced interventionalists reviewed the preoperative coronary angio-
grams of 209 patients undergoing their first coronary bypass operation (CABG) for multi-
vessel disease without other adjunctive surgical procedures at the Royal Brompton
Hospital in 2002. They were classified according to the technical feasibility and complete-
ness of percutaneous revascularisation (PCI) and a provisional strategy was declared. A
cost decision-analysis model with simulated 1 year costs was constructed with a cost of
DES at $3,360.
Results: Mean age was 64.6±8.9 years with 54 diabetics (25.8%). Each patient received
at least 1 arterial graft and a mean of 3.0±0.8 distal anastomoses. Mean post-CABG stay
was 8.9±7.2 days and total cost $22,653. Adequate PCI was judged to be unachievable
in the presence of at least 1 unfavourable total occlusion (CTO) (excessive length,
unfavourable take-off, poor visualisation of the distal vessel) subtending viable myocar-
dium in 48 patients (23%) and extreme tortuosity or calcification in 4 patients (2%). PCI
of grafted major epicardial vessels was anticipated to be complete in 138 patients (66%)
and partial but acceptable in 19 patients (9.1%). Stenting of the left main, “favourable”
CTO, bifurcations or in an ostial location were required in 32 (20.4%), 60 (38.2%), 77
(49.0%) and 74 (47.1%) respectively of cases treated. 3.6±1.4 stents of total length
72.6±37.3 mm were required to treat 3.3±1.2 lesions per patient at an estimated cost of
$22,206. One year repeat revascularisation at an assumed rate of 15% in the PCI group
resulted in a $2,250 cost excess for PCI.
Conclusions: PCI is feasible for a majority of patients undergoing multivessel CABG
with marginally lower hospital cost ($446). It demands however, the use of multiple long
stents and frequent treatment of challenging lesion subtypes. At current DES cost, PCI is
likely to remain more expensive than CABG during long term follow up.
Incidence of Early Stent Thrombosis
Bare stent SES PES p value
Incidence 5/ 500 9/ 1000 5/ 500
Percentage 1.0% 0.9% 1.2% p=0.9
